Clinical Trials Logo
  1. Home
  2. GERD
  3. NCT02028663
  4. Details
NCT02028663 Clinical Trial

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

GERD Clinical Trial

Official title:
A Double-Blind, Randomized, Dose-finding Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02028663
Other study ID # CJ_APA_201
Secondary ID
Status Completed
Phase Phase 2
First received January 5, 2014
Last updated August 6, 2014
Start date May 2013
Est. completion date May 2014

Study information
Verified date August 2014
Source CJ HealthCare Corporation
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry of Food and Drug Safety
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.

Recruitment information / eligibility
Status Completed
Enrollment 206
Est. completion date May 2014
Est. primary completion date May 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- Aged between 20-70

- Diagnosed with Erosive Esophagitis by Esophagogastroduodenoscopy (EGD) and classified into LA Grade A to D within 14 days before randomization to treatment

Exclusion Criteria:

- Patients who cannot undergo EGD

- Patients diagnosed with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected IBS

- Patients who took PPIs within 2 weeks prior to study drug administration

- Long-term use of nonsteroidal anti-in?ammatory drugs throughout the study

- Clinically significant abnormal laboratory values during screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• CJ-12420
Once daily, Oral administration
• Esomeprazole
Once daily, Oral administration

Locations
Country Name City State
Korea, Republic of Seoul National University Hospital and 11 others Seoul

Sponsors (1)
Lead Sponsor Collaborator
CJ HealthCare Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Cumulative healing rate of erosive esophagitis at 8-week 8 week No
Secondary Healing rate of erosive esophagitis at 4-week 4 week No
See also
  Status Clinical Trial Phase
Recruiting NCT06084572 - Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus
Completed NCT03568825 - Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose N/A
Recruiting NCT04703374 - A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1
Completed NCT04120025 - Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients N/A
Withdrawn NCT04771247 - Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy N/A
Completed NCT02575287 - Minimal Injuries From Esophagus Detected by Optical Enhancement System™ Associated to Optical Magnification HD Scopes N/A
Completed NCT01710800 - Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy N/A
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Completed NCT00287391 - Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT00629564 - An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT04243668 - ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA) N/A
Completed NCT03558477 - PK/PD Clinical Trial of YYD601 in Healthy Adult Male Phase 1
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Completed NCT05069493 - Long-term Follow-up After Hiatal Hernia Repair by Tension-free Mesh Closure or Simple Suturing
Completed NCT03238534 - Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS Phase 4
Recruiting NCT05974722 - Mesh Vs Pledgets for Repair of Paraesophageal Hernia N/A
Recruiting NCT05781347 - Stretta Versus Conservative Treatment in Obese and Non-obese N/A
Completed NCT06141577 - A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects Phase 1
Recruiting NCT05108038 - A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1
Recruiting NCT02587910 - Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease Phase 2/Phase 3